HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir. (21st June 2021)

• Record Type: Journal Article
• Authors: Martin, Charlène; Gracias, Ségolène; Charpentier, Charlotte; Descamps, Diane; Le Hingrat, Quentin; Plantier, Jean-Christophe; Alessandri-Gradt, Elodie
• Is Part Of: Journal of antimicrobial chemotherapy. Volume 76:Number 9(2021)
• Page Start: 2306
• Page End: 2309
• Publication Date: 2021-06-21
• Subjects: Anti-infective agents -- Periodicals; Chemotherapy -- Periodicals; 615.58
• DOI: 10.1093/jac/dkab196
• Languages: English
• ISSNs: 0305-7453

Abstract

Abstract: Objectives: HIV-1 group O (HIV-1/O) is one of the four HIV-1 groups and is endemic in Cameroon, representing 1% of HIV-1 infections in the population. Around 50% of the strains of this group naturally show a mutation (Y181C) providing them with resistance to NNRTIs and making therapeutic management more difficult. Today, the WHO recommends the use of integrase strand transfer inhibitors (INSTIs) as first-line treatment. Bictegravir and cabotegravir are the two most recent INSTIs. Because of the genetic polymorphism of HIV-1/O, studies are required to evaluate their phenotypic susceptibility to these two drugs. Patients and methods: We performed a phenotypic study on a large panel including 41 HIV-1/O clinical isolates and other rare non-group M HIV-1 (2 HIV-1/N and 1 HIV-1/P) to evaluate in vitro susceptibility to bictegravir and cabotegravir. Results: The results showed an overall susceptibility of non-group M strains to the two drugs compared with HIV-1 group M. There was no difference between the mean (min–max) IC50 of HIV-1/M [1.86 (0.93–4.12) and 5.24 (1.76–12.41) nM for bictegravir and cabotegravir, respectively] and HIV-1/non-M [2.17 (0.03–9.47) and 4.88 (0.02–15.64) nM for bictegravir and cabotegravir, respectively]. However, we found a significant difference between IC50 values for bictegravir and cabotegravir in the whole panel ( P value < 0.001). Conclusions: This study has shown encouraging results regarding the clinical use of these drugs in HIV-1/non-M-infected patients, which will need to be confirmed with clinical data.